The Association of Microbiota Composition With cGVHD After Allo-HSCT
NCT ID: NCT05355675
Last Updated: 2022-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2022-05-01
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
NCT06143501
Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
NCT02398708
Metabolome and Microbiome Impact on Acute GVHD in Recipients of Hematopoietic Transplant
NCT05186857
Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT
NCT03575767
Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03357172
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
observational group
Patients with hematologic malignancies following allogeneic hematopoietic stem cell transplantation treatment
blood sample
collecting 15ml peripheral blood samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
stool sample
collecting 50mg fresh stool samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
control group
health control group: healthy volunteers
blood sample
collecting 15ml peripheral blood samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
stool sample
collecting 50mg fresh stool samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sample
collecting 15ml peripheral blood samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
stool sample
collecting 50mg fresh stool samples at -7 days before transplantation and+28 days, +100 days, +1 years, +2 years after transplantation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. patients planned to be treated by allogeneic hematopoietic cell transplantation
3. signed written informed consent
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yi Luo
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yi Luo, M.D.
Role: PRINCIPAL_INVESTIGATOR
First Affilaated Hospital of Medical School of Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The first Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
First Affiliated Hospital of Zhejiang Chinese Medicine University
Hangzhou, Zhejiang, China
Second Affiliated Hospital of Zhejiang University, School of Medicine
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University
Hangzhou, , China
Zhejiang Provincial People's Hospital
Hangzhou, , China
Jinhua Hospital of Zhejiang University
Jinhua, , China
Ningbo Hospital of Zhejiang University
Ningbo, , China
The Affiliated People's Hospital of Ningbo University
Ningbo, , China
The Affiliated People's Hospital of Ningbo University
Ningbo, , China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Huixian Hu, MD
Role: primary
Ying Chen, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZJU-HSCT-microbe
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.